The current stock price of NVTR is 0.13 null. In the past month the price decreased by -91.72%. In the past year, price decreased by -99.26%.
ChartMill assigns a fundamental rating of 4 / 10 to NVTR. The financial health of NVTR is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months NVTR reported a non-GAAP Earnings per Share(EPS) of -2.97. The EPS increased by 16.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -104.27% | ||
| ROA | -39.89% | ||
| ROE | N/A | ||
| Debt/Equity | 0.58 |
Nuvectra Corporation develops and commercializes neuromodulation medical device for the treatment of nervous system disorders. It also provides neural interface technology, components and systems, as well as NeuroNexus SmartBox portable control and data streaming systems. Nuvectra Corporation is based in Plano, Texas.
Nuvectra Corporation
5830 GRANITE PKWY SUITE 1100
PLANO TX 75024
CEO: Fred B. Parks
Phone: 214-474-3103
Nuvectra Corporation develops and commercializes neuromodulation medical device for the treatment of nervous system disorders. It also provides neural interface technology, components and systems, as well as NeuroNexus SmartBox portable control and data streaming systems. Nuvectra Corporation is based in Plano, Texas.
The current stock price of NVTR is 0.13 null. The price decreased by -23.17% in the last trading session.
NVTR does not pay a dividend.
NVTR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Nuvectra Corporation (NVTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.97).
Nuvectra Corporation (NVTR) has a market capitalization of 2.33M null. This makes NVTR a Nano Cap stock.